CoChat

Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer’s Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial

Open access
Boada, Mercè, Anaya, Fernando, Ortiz, Pilar, Olazarán, Javier, Shua-Haim, Joshua R., Obisesan, Thomas O., Hernández, Isabel, Muñoz, Joan, Buendia, Mar, Alegret, Montserrat, Lafuente, Asunción, Tárraga, Lluís, Núñez, Laura, Torres, Mireia, Grifols, Joan Ramon, Ferrer, Isidre, Lopez, Oscar L., Páez, Antonio · 2017 · Journal of Alzheimer’s Disease

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

Background: Studies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-β (Aβ) peptide between cerebrospinal fluid (CSF) and plasma compartments. Objective: To determine whether plasma exchange (PE) with albumin replacement was able to modify Aβ concentrations in CSF and plasma as well as to improve cognition in patients with mild-moderate Alzheimer’s disease (AD). Methods: In a multicenter, randomized, patient- and rater-blind, controlled, parallel-group, phase II study, 42 AD patients were assigned (1 : 1) to PE treatment or control (sham) groups. Treated patients received a maximum of 18 PE with 5% albumin (Albutein ® , Grifols) with three different schedules: two PE/weekly (three weeks), one PE/weekly (six weeks), and one PE/bi- weekly (12 weeks), plus a six-month follow-up period. Plasma and CSF Aβ 1–40 and Aβ 1–42 levels, as well as cognitive, functional, and behavioral measures were determined. Results: CSF Aβ 1–42 levels after the last PE compared to baseline were marginally higher in PE-treated group versus controls (adjusted means of variation: 75.3 versus –45.5 pg/mL; 95% CI: –19.8, 170.5 versus 135.1, 44.2; p = 0.072). Plasma Aβ 1–42 levels were lower in the PE-treated group after each treatment period ( p < 0.05). Plasma Aβ 1–40 levels showed a saw-tooth pattern variation associated with PE. PE-treated patients scored better in the Boston Naming Test and Semantic Verbal Fluency ( p < 0.05) throughout the study. Neuropsychiatric Inventory scores were higher in controls during the PE phase ( p < 0.05). Conclusion: PE with human albumin modified CSF and plasma Aβ 1–42 levels. Patients treated with PE showed improvement in memory and language functions, which persisted after PE was discontinued.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-160565

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig.1 Flow of patients through the study.
Fig.1 Flow of patients through the study.CC BY-NC · PubMed Central
Fig.2 Levels of Aβ1–40 (A) and Aβ1–42 (B) in cerebrospinal fluid of plasma exchange (PE)-treated patients and control (sham PE) during the treatment phase and follow-up periods (Mean±SD; N = 14–19; intention-to-treat population). The p value refers to variation of adjusted (least-squares) mean of Aβ1–42 levels between the end of the last PE and baseline in the PE-treated group.
Fig.2 Levels of Aβ1–40 (A) and Aβ1–42 (B) in cerebrospinal fluid of plasma exchange (PE)-treated patients and control (sham PE) during the treatment phase and follow-up periods (Mean±SD; N = 14–19; intention-to-treat population). The p value refers to variation of adjusted (least-squares) mean of Aβ1–42 levels between the end of the last PE and baseline in the PE-treated group.CC BY-NC · PubMed Central
Fig.3 Levels of Aβ1–40 (A) and Aβ1–42 (B) in plasma of plasma exchange (PE)-treated patients and controls (sham PE) before and after each PE, during the three treatment periods (intensive, maintenance I and maintenance II) and follow-up (means without dispersion; N = 18–19; intention-to-treat population).
Fig.3 Levels of Aβ1–40 (A) and Aβ1–42 (B) in plasma of plasma exchange (PE)-treated patients and controls (sham PE) before and after each PE, during the three treatment periods (intensive, maintenance I and maintenance II) and follow-up (means without dispersion; N = 18–19; intention-to-treat population).CC BY-NC · PubMed Central
Fig.4 Score change from baseline in Mini-Mental Status Examination (MMSE) (A) and Alzheimer’s Disease Assessment Scale –Cognitive subscale (ADAS-Cog) (B) tests measured in plasma exchange (PE)-treated patients and controls (sham PE) (mean±95% CI; N = 18–19; intention-to-treat population). P-values refer to treatment effect.
Fig.4 Score change from baseline in Mini-Mental Status Examination (MMSE) (A) and Alzheimer’s Disease Assessment Scale –Cognitive subscale (ADAS-Cog) (B) tests measured in plasma exchange (PE)-treated patients and controls (sham PE) (mean±95% CI; N = 18–19; intention-to-treat population). P-values refer to treatment effect.CC BY-NC · PubMed Central
Fig.5 Score differences with respect to baseline in Boston Naming Test (BNT) (A) and Semantic Verbal Fluency (SVF) (B) tests measured in plasma exchange (PE)-treated patients and controls (sham PE) (mean±95% CI; N = 18–19; intention-to-treat population). P-values refer to treatment-by-visit effect.
Fig.5 Score differences with respect to baseline in Boston Naming Test (BNT) (A) and Semantic Verbal Fluency (SVF) (B) tests measured in plasma exchange (PE)-treated patients and controls (sham PE) (mean±95% CI; N = 18–19; intention-to-treat population). P-values refer to treatment-by-visit effect.CC BY-NC · PubMed Central
Fig.6 Score differences with respect to baseline in Neuropsychiatric Inventory (NPI) (A) and Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL) (B) tests measured in plasma exchange (PE)-treated patients and controls (sham PE) (mean±95% CI; N = 18–19; intention-to-treat population). P-values refer to treatment-by-visit effect in NPI and to treatment effect in ADCS-ADL.
Fig.6 Score differences with respect to baseline in Neuropsychiatric Inventory (NPI) (A) and Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL) (B) tests measured in plasma exchange (PE)-treated patients and controls (sham PE) (mean±95% CI; N = 18–19; intention-to-treat population). P-values refer to treatment-by-visit effect in NPI and to treatment effect in ADCS-ADL.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 4

  1. 10.1002/1531-8249(199909)46:3<412::AID-ANA19>3.0.CO;2-A · doi:10.1002/1531-8249(199909)46:3<412::aid-ana19>3.0.co;2-a
  2. Smith A, 1973, Symbol Digits Modality Test
  3. Kaplan E, 1983, The Boston naming test
  4. Costa M, 2015, J Prev Alzheimers Dis, 2, 370

Cited by

See all 94

Metadata

Authors
Boada, M., Anaya, F., Ortiz, P., Olazarán, J., Shua-Haim, J. R., Obisesan, T. O., Hernández, I., Muñoz, J., Buendia, M., Alegret, M., Lafuente, A., Tárraga, L., Núñez, L., Torres, M., Grifols, J. R., Ferrer, I., Lopez, O. L., & Páez, A.
Affiliations
  • Memory Clinic and Research Center of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain
  • Hospital General Universitario Gregorio Marañón (ES)
  • Banc de Sang i Teixits (ES)
  • Alzheimer’s Research Corporation, Mid Atlantic Geriatric Association, Manchester, NJ, USA
  • Howard University (US)
  • Fundació ACE (ES)
  • Grifols (Spain) (ES)
  • Banc de Sang i Teixits, Barcelona, Spain
  • Institut de Neuropatologia, Hospital Universitario Bellvitge, Barcelona, Spain
  • Departments of Neurology and Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, USA
Venue
Journal of Alzheimer’s Disease
Published
2016-11-28
Volume
56
Issue
1
Pages
129-143
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2559487414
Cited by
94
References
53
Citations by year
2026: 5 · 2025: 11 · 2024: 11 · 2023: 8 · 2022: 9 · 2021: 12 · 2020: 12 · 2019: 13 · 2018: 9 · 2017: 4
FWCI
6.98
Type
journal article
Language
en
Open access
Locations
  • Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
  • RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, public-domain)
Funders
  • Grifols
  • National Institutes of Health (UL1TR001409)
  • National Center for Advancing Translational Sciences
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
Keywords
plasma exchange, albumin replacement
MeSH terms
Aged, Aged, 80 and over, Albumins, Alzheimer Disease, Cognition Disorders, Female, Follow-Up Studies, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neuropsychological Tests, Plasma Exchange, Psychiatric Status Rating Scales, Tomography Scanners, X-Ray Computed, Amyloid beta-Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.